Better than the common oral therapy TYK2 structure inhibitors to treat psoriasis reached the clinical end of phase 3

At the same time, the trial reached several critical secondary endpoints, including deucravacitinib performing better than common oral PDE4 inhibitors at major endpoints in the 16th week after treatment.
psoriasis is a widespread chronic systemic immuno-mediated disease, which seriously damages the health, quality of life and work efficiency of patients.
it affects at least 100 million people worldwide and is characterized by distinct circular or oval patches, usually covered with silver-white scales.
psoriasis is associated with a variety of combinations known to reduce life expectancy, including cardiovascular disease, metabolic syndrome, obesity, diabetes, inflammatory bowel disease, depression, and malignant tumors.
Deucravacitinib is a selective TYK2 inhibitor that inhibits IL-12, IL-23, and TYPE 1 interferon (IFN) pathogenesis, which are associated with the pathogenesis of psoriasis and other immunomeufitive diseases.
Deucravacitinib is selective by combining TYK2's regulatory domain, which is structurally different from JAK1, 2 and 3 kinases.
at clinically relevant concentrations, deucravacitinib does not inhibit JAK1, 2, 3 activity.
Deucravacitinib is being studied in a variety of immuno-mediated diseases, including psoriasis, psoriasis arthritis, lupus and inflammatory bowel disease.
1020 patients in a randomized double-blind trial called POETYK PSO-2 assessed the efficacy and safety of deucravacitinib compared to placebos and common PDE4 inhibitors.
, deucravacitinib had reached its main end point in a Phase 3 clinical trial called POETYK PSO-1.
BMS said researchers will complete a comprehensive assessment of POETYK PSO-2 data and share detailed results at future medical conferences.
" Deucravacitinib is designed as a selective TYK2 inhibitor that inhibits IL-12, IL-23, and TYPE 1 IFN path pathfects associated with a variety of immunometic diseases.
the superior efficacy we have observed in patients with moderate to severe psoriasis, coupled with the safety characteristics of good tolerance, is consistent with the new mechanism of action of deucravacitinib.
. Samit Hirawat, chief medical officer of the company, said, "Deucravacitinib may be an important oral treatment option for patients with psoriasis.
we look forward to discussing with regulators the results of the POETYK PSO-1 and POETYK PSO-2 registration studies to make this new treatment available to people with this serious disease as soon as possible.
: This article is intended to introduce medical and health research, not treatment options recommended.
if you need guidance on treatment options, visit a regular hospital.
: Bristol Myers Squibb Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Show Show Superiority of Deucravacitinib Compared to Placebo and Otezla ® (apremilast). Retrieved February 2, 2021, from